ArticleProstate cancer and prostatic diseases2013
Association between metabolic syndrome, diabetes mellitus and prostate cancer risk.
Article in Prostate cancer and prostatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies.Scientific reports · 2019Pooled it
- Meta-analysis of metabolic syndrome and prostate cancer.Prostate cancer and prostatic diseases · 2017Pooled it
- Metformin use and risk of prostate cancer: results from the REDUCE study.Cancer prevention research (Philadelphia, Pa.) · 2015 · on this mapTrial
- Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.BJU international · 2015Trial
- Comparative Post-Transplant Outcomes in Alcohol-Related Liver Disease and Non-Alcohol Steatohepatitis: A Multicenter Propensity-Matched Study.Medical sciences (Basel, Switzerland) · 2026Article
- Association Between Diabetes and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis of Observational Studies.The world journal of men's health · 2025Article
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Peri-prostatic adipose tissue measurements using MRI predict prostate cancer aggressiveness in men undergoing radical prostatectomy.Journal of endocrinological investigation · 2021Article
- Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.BMC cancer · 2020Article
- Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer.Disease markers · 2018Article
- A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.Ecancermedicalscience · 2018Review
- Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men.Diabetologia · 2016Article
- Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada.BMC public health · 2015Article
- The impact of type 2 diabetes on the outcome of localized renal cell carcinoma.World journal of urology · 2014Article
- Circumcision and prostate cancer: a population-based case-control study in Montréal, Canada.BJU international · 2014Article
- Article
- Mobile health applications for the most prevalent conditions by the World Health Organization: review and analysis.Journal of medical Internet research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development.
methodsThis study consisted of 11 541 men with coronary heart disease screened to participate in a secondary cardiac prevention trial. MS was defined according to modified NCEP/ATP III criteria. Multivariable regression analysis accounting for competing risks was performed using a modified Cox proportional hazard model in order to assess the association between diabetes, the MS and the subsequent development of prostate cancer.
resultsAt baseline, subjects were classified into one of the four groups: (1) 6119 (53%) with neither diabetic mellitus nor MS, (2) 3376 (29%) with the MS but without diabetes, (3) 560 (5%) with diabetes mellitus but without MS and (4) 1486 (13%) with both conditions. Median follow-up was 12.7 years (range 0-15.7 years). During follow-up, 459 new cases of prostate cancer were recorded. The age-adjusted hazard ratio (HR) for prostate cancer was reduced in diabetic patients compared with those without diabetes, 0.54 and 95% confidence interval of 0.40-0.73. No significant association was noted between the presence of MS and prostate cancer development. On multivariate analysis, diabetes mellitus continued to protect against the development of prostate cancer, this was more pronounced in the absence of MS (HR=0.43, P=0.01 for diabetes in the absence of MS; HR=0.64, P=0.08 in the presence of MS).
conclusionsThe results of this study indicate an inverse association between type 2 diabetes mellitus and prostate cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.